Metal deposition in calcific uremic arteriolopathy

Journal of the American Academy of Dermatology

Volumn 61, Issue 1, 2009, Pages 73-79

  Amuluru, Lavanya ^a   High, Whitney ^c   Hiatt, Kim M ^b   Ranville, James ^d   Shah, Sudhir V ^a   Malik, Bilal ^a   Swaminathan, Sundararaman ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Department of Geology and Geological Engineering   (United States)

Author keywords

calcific uremic arteriolopathy; calciphylaxis; gadolinium; metals; nephrogenic systemic fibrosis

Indexed keywords

ALUMINUM; GADOLINIUM; IRON; METAL;

ADULT; AGED; ARTICLE; BIOACCUMULATION; CALCIFIC UREMIC ARTERIOLOPATHY; CALCINOSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; PATHOGENESIS; PRIORITY JOURNAL; SKIN BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ALUMINUM; ARTERIAL OCCLUSIVE DISEASES; ARTERIOLES; CALCIPHYLAXIS; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RETROSPECTIVE STUDIES; SKIN; SKIN DISEASES;

EID: 67349222052     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.01.042     Document Type: Article

References (44)

1. Bleyer A., Choi M., Igwemezie B., de la Torre E., and White W.L. A case control study of proximal calciphylaxis. Am J Kidney Dis 32 (1998) 376-383
2. Coates T., Kirkland G.S., Dymock R.B., Murphy B.F., Brealey J.K., Mathew T.H., et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32 (1998) 384-391
3. Lewis K.G., and Robinson-Bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 33 (2006) 695-700
4. Fine A., and Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61 (2002) 2210-2217
5. Reed K.B., and Davis M.D. The incidence of physician-diagnosed calciphylaxis: a population-based study. J Am Acad Dermatol 57 (2007) 365-366
6. Gabbiani G., Tuchweber B., and Perrault G. Studies in the mechanism of metal-induced soft tissue calcification. Calcif Tissue Res 6 (1970) 20-31
7. Moe S.M., and Chen N.X. Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol 18 (2003) 969-975
8. Nigwekar S.U., Wolf M., Sterns R.H., and Hix J.K. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3 (2008) 1139-1143
9. Mawad H.W., Sawaya B.P., Sarin R., and Malluche H.H. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52 (1999) 160-166
10. Llach F. The evolving clinical features of calciphylaxis. Kidney Int 63 (2003) S122-S124
11. Mazhar A.R., Johnson R.J., Gillen D., Stivelman J.C., Ryan M.J., Davis C.L., et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60 (2001) 324-332
12. Janigan D.T., Hirsch D.J., Klassen G.A., and MacDonald A.S. Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure. Am J Kidney Dis 35 (2000) 588-597
13. Wilmer W.A., and Magro C.M. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15 (2002) 172-186
14. Slough S., Servila K.S., Harford A.M., Konstantinov K.N., Harris A., and Tzamaloukas A.H. Association between calciphylaxis and inflammation in two patients on chronic dialysis. Adv Perit Dial 22 (2006) 171-174
15. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 (2003) 357-366
16. Garrett I.R., and McClure J. Lanthanide-induced calcergy. J Pathol 135 (1981) 67-75
17. Selye H. Calciphylaxis (1962), University of Chicago Press, Chicago p. 15-40
18. Selye H., and Berczi I. The present status of calciphylaxis and calcergy. Clin Orthop 69 (1970) 28-54
19. Zacharias J.M., Fontaine B., and Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int 19 (1999) 248-252
20. Weenig R.H., Sewell L.D., Davis M.D.P., McCarthy J.T., and Pittelkow M.R. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56 (2006) 569-579
21. Edsall L.C., English III J.C., Teague M.W., and Patterson J.W. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 7 (2004) 518
22. Swaminathan S., and Shah S.V. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18 (2007) 2636-2643
23. Swaminathan S., High W.A., Ranville J., Horn T.D., Hiatt K., Thomas M., et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73 (2008) 1413-1418
24. Swaminathan S., Horn T.D., Pellowski D., Abul-Ezz S., Bornhorst J.A., Viswamitra S., et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357 (2007) 720-722
25. Essary L.R., and Wick M.R. Cutaneous calciphylaxis: an underrecognized clinicopathologic entity. Am J Clin Pathol 113 (2000) 280-287
26. Shah S.V. Role of iron in atherosclerosis. Am J Kidney Dis 41 (2003) S80-S83
27. DeVoto E., and Yokel R.A. The biological speciation and toxicokinetics of aluminum. Environ Health Perspect 102 (1994) 940-951
28. Ahmed S., O'Neill K.D., Hood A.F., Evan A.P., and Moe S.M. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 37 (2001) 1267-1276
29. Bohrer D., Bertagnolli D.C., de Oliveira S.M., do Nascimento P.C., de Carvalho L.M., and Pomblum S.G. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant 22 (2007) 605-611
30. Abraham J.L., Thakral C., Skov L., Rossen K., and Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 58 (2008) 273-280
31. Van Landeghem G.F., D'Haese P.C., Lamberts L.V., and De Broe M.E. Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients?. Exp Nephrol 5 (1997) 239-245
32. Rüster M., Abendroth K., Lehmann G., and Stein G. Aluminum deposition in the bone of patients with chronic renal failure-detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine. Clin Nephrol 58 (2002) 305-312
33. Canfield A.E., Farrington C., Dziobon M.D., Boot-Handford R.P., Heagerty A.M., Kumar S.N., et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 196 (2002) 228-234
34. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor runx-2 by akt signaling. J Biol Chem 283 (2008) 15319-15327
35. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., and Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63 (2003) 1003-1011
36. Becaria A., Campbell A., and Bondy S.C. Aluminum as a toxicant. Toxicol Ind Health 18 (2002) 309-320
37. Popat K.C., Chatvanichkul K.I., Barnes G.L., Latempa T.J.J., Grimes C.A., and Desai T.A. Osteogenic differentiation of marrow stromal cells cultured on nanoporous alumina surfaces. J Biomed Mater Res A 80 (2007) 955-964
38. Quarles L.D. A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 19 (2004) 862-869
39. Quarles L.D., Hartle II J.E., Middleton J.P., Zhang J., Arthur J.M., and Raymond J.R. Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem 56 (1994) 106-117
40. Quarles L.D., Wenstrup R.J., Castillo S.A., and Drezner M.K. Aluminum-induced mitogenesis in MC3T3-E1 osteoblasts: potential mechanism underlying neoosteogenesis. Endocrinology 128 (1991) 3144-3151
41. McClure J. The production of heterotopic calcification by certain chemical salts. J Pathol 131 (1980) 21-33
42. Johansson O., Perrault G., Savoie L., and Tuchweber B. Action of various metallic chlorides on calcemia and phosphatemia. Br J Pharmacol 33 (1968) 333-340
43. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
44. Schroeder J.A., Weingart C., Coras B., Hausser I., Reinhold S., Mack M., et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3 (2008) 968-975